[go: up one dir, main page]

DK0489579T3 - Peptidylderivater - Google Patents

Peptidylderivater

Info

Publication number
DK0489579T3
DK0489579T3 DK91311254.6T DK91311254T DK0489579T3 DK 0489579 T3 DK0489579 T3 DK 0489579T3 DK 91311254 T DK91311254 T DK 91311254T DK 0489579 T3 DK0489579 T3 DK 0489579T3
Authority
DK
Denmark
Prior art keywords
group
alkyl
amino
alkenyl
hydrogen atom
Prior art date
Application number
DK91311254.6T
Other languages
English (en)
Inventor
Thomas Andrew Millican
John Robert Porter
John Richard Morphy
Nigel Robert Arnold Beeley
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909026251A external-priority patent/GB9026251D0/en
Priority claimed from GB919110339A external-priority patent/GB9110339D0/en
Priority claimed from GB919110338A external-priority patent/GB9110338D0/en
Priority claimed from GB919112901A external-priority patent/GB9112901D0/en
Priority claimed from GB919112888A external-priority patent/GB9112888D0/en
Priority claimed from GB919115038A external-priority patent/GB9115038D0/en
Priority claimed from GB919115039A external-priority patent/GB9115039D0/en
Priority claimed from GB919115916A external-priority patent/GB9115916D0/en
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of DK0489579T3 publication Critical patent/DK0489579T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
DK91311254.6T 1990-12-03 1991-12-03 Peptidylderivater DK0489579T3 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB909026251A GB9026251D0 (en) 1990-12-03 1990-12-03 Netalloproteinase inhibitors
GB919110339A GB9110339D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919110338A GB9110338D0 (en) 1991-05-13 1991-05-13 Metalloproteinase inhibitors
GB919112901A GB9112901D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919112888A GB9112888D0 (en) 1991-06-14 1991-06-14 Metalloproteinase inhibitors
GB919115038A GB9115038D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115039A GB9115039D0 (en) 1991-07-11 1991-07-11 Metalloproteinase inhibitors
GB919115916A GB9115916D0 (en) 1991-07-23 1991-07-23 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
DK0489579T3 true DK0489579T3 (da) 1995-06-12

Family

ID=27571285

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91311254.6T DK0489579T3 (da) 1990-12-03 1991-12-03 Peptidylderivater

Country Status (16)

Country Link
US (1) US5300501A (da)
EP (2) EP0489577B1 (da)
JP (2) JPH05503720A (da)
KR (2) KR927003521A (da)
AT (2) ATE120451T1 (da)
AU (2) AU652596B2 (da)
CA (2) CA2073510A1 (da)
DE (2) DE69108529T2 (da)
DK (1) DK0489579T3 (da)
ES (1) ES2069833T3 (da)
FI (2) FI923494A0 (da)
GB (2) GB2255339B (da)
GR (1) GR3015567T3 (da)
HU (3) HUT61973A (da)
NO (2) NO922968L (da)
WO (2) WO1992009564A1 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
JP3348725B2 (ja) * 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
WO1994007481A1 (en) * 1992-10-02 1994-04-14 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
AU679474B2 (en) * 1992-11-25 1997-07-03 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
ATE169621T1 (de) * 1993-03-16 1998-08-15 British Biotech Pharm Hydroxamsaeurederivate als metalloproteinase inhibitoren
CA2160139A1 (en) * 1993-04-07 1994-10-13 Richard Edward Galardy Synthetic matrix metalloprotease inhibitors and uses thereof
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
US5714491A (en) * 1993-04-27 1998-02-03 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
JPH09503492A (ja) * 1993-08-02 1997-04-08 セルテック・セラピューティクス・リミテッド スクシンアミド誘導体、それらの調製法及びそれらのゼラチナーゼ及びコラゲナーゼ阻害剤としての使用
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
ES2144819T3 (es) * 1994-01-20 2000-06-16 British Biotech Pharm L-terc-leucina-2-piridilamida.
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
DE69510198T2 (de) * 1994-05-28 1999-10-28 British Biotech Pharmaceuticals Ltd., Cowley Succinyl hydroxamsäure-, n-formyl-n-hydroxy-aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease-inhibitoren
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
ATE191468T1 (de) * 1994-06-22 2000-04-15 British Biotech Pharm Metalloproteinase inhibitoren
US5831004A (en) 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5857961A (en) * 1995-06-07 1999-01-12 Clarus Medical Systems, Inc. Surgical instrument for use with a viewing system
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
IT1277904B1 (it) * 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
AU711804B2 (en) * 1995-11-23 1999-10-21 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
DE69626684T2 (de) * 1995-12-08 2004-04-29 Agouron Pharmaceuticals, Inc., La Jolla Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
GB9613547D0 (en) * 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
GB2324528B (en) 1996-09-10 2000-07-26 British Biotech Pharm Cytostatic hydroxamic acid derivatives
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JPH10130217A (ja) * 1996-11-01 1998-05-19 Kotobuki Seiyaku Kk カルボン酸及びその誘導体及びその製造法並びにこれを含有する医薬組成物
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0887077A1 (de) * 1997-06-27 1998-12-30 Roche Diagnostics GmbH Verwendung von Azulenderivaten als Metalloproteaseinhibitoren
GB9803005D0 (en) 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
JP2001031637A (ja) * 1999-05-17 2001-02-06 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体
BR0010637A (pt) * 1999-05-17 2002-02-19 Daiichi Fine Chem Co Ltd Composto, processo para produzir um composto, composição farmacêutica ou veterinária, inibidor de metaloproteinase, e, medicamento profilático e/ou terapêutico para doenças e/ou distúrbios associados com a degradação de tecido
CO5210860A1 (es) 1999-10-01 2002-10-30 Hoffmann La Roche Nuevos derivados de pirimidina-2,4,6-triona
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
EP1406893B1 (en) 2001-06-15 2007-04-18 Vicuron Pharmaceuticals, Inc. Pyrrolidine bicyclic compounds
US7605132B2 (en) * 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
WO2005090387A2 (en) * 2004-03-23 2005-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone h2a peptide derivatives and analogs and methods of use thereof
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
EP1585555A2 (en) * 2002-12-27 2005-10-19 Angiotech International Ag Compositions and methods of using collagen and mmpi
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
DE102014206916A1 (de) 2014-04-10 2015-10-15 Wacker Chemie Ag Verfahren zur Ruthenium-katalysierten Umvinylierung von Carbonsäuren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5196412A (en) * 1991-03-06 1993-03-23 Johnson Matthey, Inc. Gallium compounds

Also Published As

Publication number Publication date
GB9211714D0 (en) 1992-08-26
NO922968L (no) 1992-09-24
FI923495A0 (fi) 1992-08-03
EP0489577B1 (en) 1995-03-22
GB2255339A (en) 1992-11-04
DE69108363T2 (de) 1995-08-31
NO922967L (no) 1992-09-24
JPH05503719A (ja) 1993-06-17
NO922967D0 (no) 1992-07-28
GB9211715D0 (en) 1992-08-26
FI923495A7 (fi) 1992-08-03
ES2069833T3 (es) 1995-05-16
WO1992009565A1 (en) 1992-06-11
GR3015567T3 (en) 1995-06-30
WO1992009564A1 (en) 1992-06-11
FI923494L (fi) 1992-08-03
EP0489577A1 (en) 1992-06-10
HUT62263A (en) 1993-04-28
CA2073510A1 (en) 1992-06-04
AU652596B2 (en) 1994-09-01
DE69108529D1 (de) 1995-05-04
FI923494A7 (fi) 1992-08-03
KR927003520A (ko) 1992-12-18
GB2255340B (en) 1994-09-28
CA2073513A1 (en) 1992-06-04
ATE120182T1 (de) 1995-04-15
HU9202498D0 (en) 1992-10-28
GB2255340A (en) 1992-11-04
ATE120451T1 (de) 1995-04-15
DE69108529T2 (de) 1995-11-30
FI923494A0 (fi) 1992-08-03
NO922968D0 (no) 1992-07-28
JPH05503720A (ja) 1993-06-17
KR927003521A (ko) 1992-12-18
EP0489579B1 (en) 1995-03-29
DE69108363D1 (de) 1995-04-27
AU652793B2 (en) 1994-09-08
GB2255339B (en) 1994-10-05
HUT61973A (en) 1993-03-29
AU9017391A (en) 1992-06-25
EP0489579A1 (en) 1992-06-10
HU9202497D0 (en) 1992-10-28
US5300501A (en) 1994-04-05
AU9023391A (en) 1992-06-25

Similar Documents

Publication Publication Date Title
DK0489579T3 (da) Peptidylderivater
AU645867B2 (en) 2-arylthiazole derivative and pharmaceutical composition containing the same
NO171684C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktiv polyetylenglykolkarbaminater
NO914356D0 (no) Mono n-substituerte 1,4,7,10-tetraazacyklododecan-derivater
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
AU565400B2 (en) 2-azaspiro(4 )-3-carboxylic acid derivatives
MY131193A (en) 7-(2-aminoethyl)-benzothiazolones
ATE110725T1 (de) Organische salze von physostigminderivaten.
CA2102209A1 (en) Novel Isoxazole Derivative and Salt Thereof
ATE230740T1 (de) Piperidinylpyrimidine derivate
DK0487620T3 (da) Hidtil ukendte aminosyrederivater, fremgangsmåde til fremstilling heraf og terapeutisk anvendelse heraf
DE59915244D1 (de) Kosmetische oder pharmazeutische Zubereitungen enthaltend 1,3,5-Triazinderivate und Zinkoxid
ES2012958A6 (es) Procedimiento para preparar derivados de cisteina.
GR3005865T3 (da)
DK363284A (da) Endo-8,8-dialkyl-8-azoniabicyclo/3.2.1/octan-6,7-exo-epoxy-3-alkylcarboxylatsalte, fremgangsmaade til fremstilling heraf og terapeutiske praeparater indeholdende disse
ES8404785A1 (es) Procedimiento para la fabricacion de nicotinamida 1-oxido n-substituida y sus sales
DE3861545D1 (de) Aminoverbindungen und diese enthaltende fungizide.
DK656889A (da) Azabicykliske derivater
ES8602019A1 (es) Un procedimiento para preparar compuestos de cefalosporina
MD122C2 (ro) Procedeu de obţinere a derivaţilor oxadiazolilalchilpurinei sau a sărurilor ei acide aditive farmacologic acceptabile